Drs. Lisa Schwartz and Steven Woloshin write that much critical information that the FDA has at the time of approval may fail to make its way into the drug label and relevant journal articles.
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2009) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: